For the study, Henry Ford researcher and lead author Josena Stephen, M.D., and Dr. Worsham looked at 80 patients with laryngeal squamous cell cancer who were diagnosed between 1996 and 2008. Forty percent of the study group was African American.
Using tissue DNA samples the researchers examined the methylation status of 24 tumor suppressor genes and tested for the presence of the human papilloma virus (HPV). DNA methylation a type of chemical modification of DNA where a methyl group (CH3) can be added (hypermethylation) or removed (hypomethylation) allows the researchers to look for genetic abnormalities within tumor samples.
The study found: Abnormal DNA methylation of ESR1 predicted late stage disease. African Americans are more likely to have advanced stage disease than their Caucasian counterparts, a finding consistent with previous research. Abnormal DNA methylation of HIC1, late stage disease, and vascular invasion were predictors of shorter survival. The median survival for patients in the study group was 4.2 years. HPV was much higher in this group of patients (37 percent), supporting the role of HPV in laryngeal cancer. The majority of patients were either current or past smokers and alcohol users, again confirming the role these factors play in laryngeal cancer.
"When this research crosses from the lab to clinical care, the contribution of specific gene changes will assist in improving the accuracy of cancer staging and length of survival for laryngeal cancer patients," explains Dr. Worsham.
"So if a patient comes in with stage 1, based on current standards, and then we find methylation of ESR1, the patient may have underpinnings of a more aggressive tumor with characteristics that are more in line with a stage 3 or stage 4 diagnosis, refining treatment options."
Source-Eurekalert
ARU